Off to @Jefferies Global Healthcare conference in London! Looking forward to connecting with investors and fellow innovators who share our belief that mitochondrial medicine is becoming one of the most important frontiers in biotech.
#JefferiesHealthcare #MitochondrialMedicine
1
56
Next week marks the Externally-Led PFDD Meeting on POLG-Related Disorders.
Individuals affected by POLG are encouraged to attend and be part of shaping the future of mito disease care and treatment. To learn more about participation visit bit.ly/4iwta7b
26
Looking forward to connecting this week at #NSCG26!
Stop by 1361 to learn about our work in Barth syndrome and mitochondrial medicine.
#RareDisease #MitochondrialDisease
33
Mighty Therapeutics retweeted
NORD honored @Mighty_Tx with a 2026 Industry Innovator #RareImpactAward for developing the first FDA-approved therapy for #BarthSyndrome.
Presented by NORD CEO Pamela Gavin alongside @BarthSyndrome Foundation Co-founder Kate McCurdy, the award celebrates decades of advocacy and research that have brought new hope to families.
Learn more: rareimpact.org
Mighty Therapeutics' CSO will be at #ICAR2026, presenting new preclinical research in Friedreich’s ataxia. If you’re attending ICAR, stop by our poster (EP17) to talk mitochondrial science. We’d love to connect!
Today, Mighty Therapeutics announced a commercial update and pipeline progress across its mitochondrial disease portfolio. Read the press release here: bit.ly/4hP3m5K
34
The Mighty team is excited to be at the FA Symposium hosted by @CureFA_org and CHOP.
We are looking forward to learning from leading experts, patients & caregivers, & connecting with others who share our commitment to advancing care for those affected by mitochondrial disease.
48
Join us at the @RetinaSociety Annual Meeting this week! The Mighty team (formerly Stealth) looks forward to discussing our mito-targeted therapies for #dryAMD.
Reach out to learn more or schedule time to connect with us: [email protected]
#RetinaSociety #dryAMD
55
Mito disease impacts individuals and families in countless ways. Behind every diagnosis is a unique journey filled with challenges, resilience, hope, and determination. This #MDAW, we’re honored to introduce you to three families impacted by mito disease and share their stories.
2
57
Mighty Tx announces development of a novel preclinical model for Parkinson’s disease, mitochondrial diseases driven by POLG mutations, and other mitochondrial diseases characterized by neurodegeneration. Read the full press release here: bit.ly/4rbOBhV
2
40
Mighty announces advancement of its pipeline compound into IND-enabling studies. Read the full press release here: bit.ly/4yqXYfQ
1
40
Mighty Therapeutics together with a joint research team from the University of Washington led by Dr. David Marcinek, has been named a Milestone 2 Awardee in the @xprize Healthspan competition!
To learn more, read the full press release here: bit.ly/3SnkIhw
We are pleased to announce we have entered into agreements with K2 HealthVentures and Morningside securing up to $150 million to progress commercial and clinical development of new class of mitochondrial targeted medicines. Read the full announcement here: bit.ly/3RdevUI
66
We are pleased to share an update on our Phase 4 trial in Barth syndrome and upcoming presentations at the Biennial @BarthSyndrome Foundation International Scientific, Medical & Family Conference. Read the press release here: bit.ly/3SGrwH0
64
We are excited for an action packed @UMDF #MitoMed conference this week in Orlando! Stop by our booth to learn more about our latest updates in #MitochondrialMedicine.
We are pleased to announce that Stealth BioTherapeutics has rebranded as Mighty Therapeutics!
Our new name reflects the strength of the patients and families who inspire our work, and our commitment to advancing mitochondrial medicine.
Learn more here: bit.ly/44hOkPz
1
71
We’ll be in attendance at @OrphanConf this week! Come check out the following sessions that members of the Stealth team will be participating in.
#WODC2026
33
Stealth will be participating at today’s @reaganudall meeting on Affecting the Aging Trajectory. We look forward to contributing to productive discussions on regulatory frameworks for therapies targeting aging biology. Learn more about today's session at: bit.ly/42ZXoYT
36
We are pleased to announce presentations on our latest research in mitochondrial medicine at the upcoming #Euromit2026 congress! Read the full press release here: bit.ly/4f452J5
71
#ICYMI Stealth BioTherapeutics announced a commercial and pipeline update. Learn more in the press release: bit.ly/4t8NqiB
55




















